Cosmos Health secures exclusive distribution agreement with Virax Biolabs

Cosmos Health (COSM) has entered into a distribution agreement with Virax Biolabs Group (VRAX) to distribute Virax-branded Avian Influenza Virus Real-Time PCR Kits across various major European markets and certain Gulf Cooperation Council countries. Specifically, Cosmos Health gains exclusive rights to distribute these kits in Greece and Cyprus, as well as non-exclusive rights in select European countries, including France, Portugal, Spain, The Netherlands, Belgium, Sweden, Finland, Denmark, Norway, Germany, Switzerland, and Austria. The agreement also grants non-exclusive distribution rights in certain Gulf Cooperation Council countries, namely Oman and Bahrain. These specialized RT-PCR tests reliably detect ribonucleic acid from AIV, including the H5, H7, and H9 subtypes, such as the globally concerning H5N1 strain. By enabling healthcare professionals to quickly identify infections, the kits play a crucial role in screening individuals exposed to infected livestock or high-risk environments, supporting effective public health responses. Under the agreement, Cosmos Health is authorized to import, sell, and distribute ViraxClear-branded kits within the agreed territories, while Virax will oversee regulatory compliance and provide the necessary documentation to support product registration and approval in these regions.